JP2017523206A - ブルトン型チロシンキナーゼ阻害剤の新規製剤 - Google Patents

ブルトン型チロシンキナーゼ阻害剤の新規製剤 Download PDF

Info

Publication number
JP2017523206A
JP2017523206A JP2017505606A JP2017505606A JP2017523206A JP 2017523206 A JP2017523206 A JP 2017523206A JP 2017505606 A JP2017505606 A JP 2017505606A JP 2017505606 A JP2017505606 A JP 2017505606A JP 2017523206 A JP2017523206 A JP 2017523206A
Authority
JP
Japan
Prior art keywords
formulation
ibrutinib
compound
polymer
solid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017505606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523206A5 (enExample
Inventor
シュ，カサンドラ
アトゥルーリ，ハリシャ
キュール，ロバート
シュウェ−チョ タイ，パール
シュウェ−チョ タイ，パール
ミッチェル ミンキス，ライアン
ミッチェル ミンキス，ライアン
フランシス フルバット，ジェイムス
フランシス フルバット，ジェイムス
ジェイコブ マクベイ，アレキサンダー
ジェイコブ マクベイ，アレキサンダー
チョン，チン−ワ
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー filed Critical ファーマサイクリックス エルエルシー
Publication of JP2017523206A publication Critical patent/JP2017523206A/ja
Publication of JP2017523206A5 publication Critical patent/JP2017523206A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017505606A 2014-08-07 2015-08-07 ブルトン型チロシンキナーゼ阻害剤の新規製剤 Pending JP2017523206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034353P 2014-08-07 2014-08-07
US62/034,353 2014-08-07
PCT/US2015/044258 WO2016022942A1 (en) 2014-08-07 2015-08-07 Novel formulations of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2017523206A true JP2017523206A (ja) 2017-08-17
JP2017523206A5 JP2017523206A5 (enExample) 2018-09-20

Family

ID=55264642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505606A Pending JP2017523206A (ja) 2014-08-07 2015-08-07 ブルトン型チロシンキナーゼ阻害剤の新規製剤

Country Status (13)

Country Link
US (4) US9545407B2 (enExample)
EP (1) EP3193877A4 (enExample)
JP (1) JP2017523206A (enExample)
KR (1) KR20170033358A (enExample)
CN (1) CN106573002A (enExample)
AU (1) AU2015300798A1 (enExample)
BR (1) BR112017002231A2 (enExample)
CA (1) CA2955747A1 (enExample)
IL (1) IL250085A0 (enExample)
MX (1) MX2017001671A (enExample)
RU (1) RU2017106795A (enExample)
SG (1) SG11201700849XA (enExample)
WO (1) WO2016022942A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532159A (ja) * 2018-07-31 2021-11-25 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. （ｓ）−５−アミノ−３−（４−（（５−フルオロ−２−メトキシベンズアミド）メチル）フェニル）−１−（１，１，１−トリフルオロプロパン−２−イル）−１ｈ−ピラゾール−４−カルボキサミドの噴霧乾燥分散体および製剤
JP2022525797A (ja) * 2019-04-11 2022-05-19 ゴールドフィンチ バイオ，インク． ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP2022533368A (ja) * 2019-05-17 2022-07-22 セルジーン シーエーアール エルエルシー Ｍｋ２媒介性障害の治療方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
KR20170033358A (ko) * 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
HK1250925A1 (zh) * 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
MX2018008771A (es) * 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.
KR20190138871A (ko) * 2017-04-24 2019-12-16 사무스 테라퓨틱스, 인코포레이티드 Hsp90 저해제 경구 제형 및 관련 방법
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
CN110996913A (zh) * 2017-06-30 2020-04-10 欧恩科斯欧公司 新的贝利司他口服制剂
RU2767872C2 (ru) * 2017-07-04 2022-03-22 Цзянсу Хэнжуй Медсин Ко., Лтд. Фармацевтическая композиция и способ ее получения
CN110913840A (zh) * 2017-08-11 2020-03-24 默克专利股份公司 包含3-氟-4-[7-甲氧基-3-甲基-8-(1-甲基-1H-吡唑-4-基)-2-氧代-2,3-二氢-咪唑并[4,5-c]喹啉-1-基]-苄腈的药物制剂
US20200268761A1 (en) 2017-09-19 2020-08-27 Cipla Limited Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CZ2017787A3 (cs) * 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CA3089537A1 (en) * 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
BR112020024481A2 (pt) 2018-06-15 2021-03-02 Janssen Pharmaceutica Nv formulações/composições compreendendo ibrutinib
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
CA3149182A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
BR112022019846A2 (pt) 2020-04-03 2022-11-22 Genentech Inc Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos
WO2021222739A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN111617028A (zh) * 2020-07-14 2020-09-04 扬子江药业集团江苏紫龙药业有限公司 一种含伊布替尼的口服制剂及制备方法
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
CN114681424A (zh) * 2020-12-31 2022-07-01 鲁南制药集团股份有限公司 一种伊布替尼胶囊及其制备方法
US11529351B2 (en) * 2021-01-21 2022-12-20 Xspray Pharma Ab Fast dissolving pharmaceutical compositions
US20240024248A1 (en) * 2021-01-21 2024-01-25 Xspray Pharma Ab Fast dissolving pharmaceutical compositions
WO2022187822A1 (en) * 2021-03-03 2022-09-09 Oakwood Laboratories, Llc Microsphere formulations comprising btk inhibitors and methods for making and using the same
CN113509443B (zh) * 2021-07-14 2023-04-11 药源生物科技（启东）有限公司 一种含soluplus的固分体及其制备方法
US20250144100A1 (en) * 2021-12-10 2025-05-08 Synthon B.V. Pharmaceutical composition comprising ibrutinib
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115054603A (zh) * 2022-06-20 2022-09-16 上海宣泰医药科技股份有限公司 依鲁替尼药物组合物及其制备方法和药物制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229887A (ja) * 1999-02-10 2000-08-22 Pfizer Prod Inc 医薬用固体分散物
JP2001527044A (ja) * 1997-12-31 2001-12-25 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
JP2004521918A (ja) * 2001-02-27 2004-07-22 アストラゼネカ アクチボラグ 医薬製剤
JP2007504103A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む固体分散体
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
US20130338172A1 (en) * 2012-06-04 2013-12-19 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3303707A1 (de) 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
CA2384378C (en) 1999-10-06 2011-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2001041754A2 (en) 1999-11-30 2001-06-14 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
GB0108903D0 (en) 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
AU2002236692A1 (en) 2000-10-23 2002-05-21 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use
US20030035833A1 (en) 2000-12-06 2003-02-20 Xiaorong He Rapidly dispersing pharmaceutical composition
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
MXPA04004814A (es) 2001-11-21 2004-08-11 Sunesis Pharmaceuticals Inc Metodos para descubrir ligandos.
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20070281907A1 (en) 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
AU2005228845A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
CN101065374A (zh) 2004-09-28 2007-10-31 詹森药业有限公司 取代的二哌啶化学引诱物细胞因子受体2拮抗剂
AU2005304473A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
ATE482693T1 (de) 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
US8183248B2 (en) 2005-05-13 2012-05-22 Irm Llc Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
WO2007058832A2 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
ES2420834T3 (es) 2006-01-30 2013-08-27 The Scripps Research Institute Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
CN101835755B (zh) 2007-10-23 2013-12-11 霍夫曼-拉罗奇有限公司 激酶抑制剂
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
MX2010011314A (es) 2008-04-14 2010-11-12 Ardea Biosciences Inc Composiciones y metodos de preparacion y uso de las mismas.
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP2317857B1 (en) 2008-07-29 2016-12-28 Frontier Scientific, Inc. Use of tetrakis(n-alkylpyridinium)-porphyrin derivatives for killing microbes or preventing their growth
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
CN103813794A (zh) 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2802314B1 (en) 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
WO2014179528A2 (en) 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
WO2015034478A1 (en) 2013-09-04 2015-03-12 Halliburton Energy Services, Inc. Scale-inhibiting cocrystals for treatment of a subterranean formation
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
CN106008516A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
WO2015123654A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US20150267752A1 (en) 2014-03-19 2015-09-24 Roller Bearing Company Of America, Inc. Bearing outer race having a radially inwardly biased seal
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015145415A2 (en) 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105085529A (zh) 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US20150110871A1 (en) 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
WO2016007617A2 (en) 2014-07-09 2016-01-14 Novotec Consulting, Llc. Pharmaceutical compounding kit
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016020697A1 (en) 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
KR20170033358A (ko) * 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
US10035802B2 (en) 2014-08-14 2018-07-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ibrutinib
WO2016050422A1 (en) 2014-10-01 2016-04-07 Ratiopharm Gmbh Acid addition salt of ibrutinib
CN104523695A (zh) 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN105640961A (zh) 2014-11-18 2016-06-08 山东瑞禾医药科技有限公司 一种含依鲁替尼的药物组合物
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
US20150224060A1 (en) 2015-01-03 2015-08-13 David Wong Gastric retentive tablet compositions
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
JP2018511580A (ja) 2015-03-03 2018-04-26 ドクター レディズ ラボラトリーズ リミテッド イブルチニブの多形体
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3277688B1 (en) 2015-04-02 2019-05-08 ratiopharm GmbH Co-crystals of ibrutinib
HK1250925A1 (zh) 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
CN105294696A (zh) 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN105440040B (zh) 2015-12-23 2018-03-13 浙江京新药业股份有限公司 依鲁替尼的纯化方法
CN105646484A (zh) 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN105646499A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
CN105646498A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN106619643A (zh) 2016-11-11 2017-05-10 上海雅本化学有限公司 一种含依鲁替尼的药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527044A (ja) * 1997-12-31 2001-12-25 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
JP2000229887A (ja) * 1999-02-10 2000-08-22 Pfizer Prod Inc 医薬用固体分散物
JP2004521918A (ja) * 2001-02-27 2004-07-22 アストラゼネカ アクチボラグ 医薬製剤
JP2007504103A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む固体分散体
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
US20130338172A1 (en) * 2012-06-04 2013-12-19 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532159A (ja) * 2018-07-31 2021-11-25 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. （ｓ）−５−アミノ−３−（４−（（５−フルオロ−２−メトキシベンズアミド）メチル）フェニル）−１−（１，１，１−トリフルオロプロパン−２−イル）−１ｈ−ピラゾール−４−カルボキサミドの噴霧乾燥分散体および製剤
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー， インコーポレイテッド （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
JP2022525797A (ja) * 2019-04-11 2022-05-19 ゴールドフィンチ バイオ，インク． ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP7607577B2 (ja) 2019-04-11 2024-12-27 ゴールドフィンチ バイオ，インク． ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP2022533368A (ja) * 2019-05-17 2022-07-22 セルジーン シーエーアール エルエルシー Ｍｋ２媒介性障害の治療方法

Also Published As

Publication number Publication date
US20160038496A1 (en) 2016-02-11
RU2017106795A3 (enExample) 2019-04-12
EP3193877A4 (en) 2018-04-04
RU2017106795A (ru) 2018-09-07
AU2015300798A1 (en) 2017-02-02
EP3193877A1 (en) 2017-07-26
CA2955747A1 (en) 2016-02-11
US20180028537A1 (en) 2018-02-01
US9545407B2 (en) 2017-01-17
MX2017001671A (es) 2017-07-04
KR20170033358A (ko) 2017-03-24
US20170079981A1 (en) 2017-03-23
BR112017002231A2 (pt) 2018-07-17
SG11201700849XA (en) 2017-03-30
IL250085A0 (en) 2017-03-30
CN106573002A (zh) 2017-04-19
US20190282578A1 (en) 2019-09-19
WO2016022942A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
US12551448B2 (en) Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US9545407B2 (en) Formulations of a bruton's tyrosine kinase inhibitor
JP2025186225A (ja) ブルトン型チロシンキナーゼ阻害剤の結晶形態
US20190367519A1 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
KR20240087693A (ko) 암 치료를 위한 비가역적 메닌-mll 억제제인 n-[4-[4-(4-모르폴리닐)-7h-피롤로[2,3-d]피리미딘-6-일]페닐]-4-[[3(r)-[(1-옥소-2-프로펜-1-일)아미노]-1-피페리디닐]메틸]-2-피리딘카르복스아미드의 결정질 형태
JP2018509458A (ja) ブルトン型チロシンキナーゼ阻害剤の共結晶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200629